ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-18W18029
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Porcine Circovirus Mycoplasma Hyopneumoniae Vaccine Market Research Report 2024
BUY CHAPTERS

Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-18W18029
Report
October 2025
Pages:149
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Boehringer Ingelheim
Zoetis Inc
Merck
Pharmgate
Ceva
SPAH
Jinyu Biotechnology
Huizhong Biological
Jiangsu Nannong Hi-Tech

Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market

The global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Porcine circovirus (PCV) and Mycoplasma hyopneumoniae (MHP) vaccine is a vaccine used to prevent important swine diseases such as porcine circovirus (PCV) and mycoplasma swine pneumonia (MHP). This vaccine combines immune protection against two major diseases and is designed to improve the health and production performance of porcine herds.
From a downstream perspective, Piglet accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine leading manufacturers including Boehringer Ingelheim, Zoetis, Merck, Pharmgate, Ceva, Huizhong Biological, Jiangsu Nannong Hi-Tech, SPAH, Jinyu Biotechnology, etc., dominate supply; the top five capture approximately % of global revenue, with Boehringer Ingelheim leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Report

Report Metric Details
Report Name Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market
Segment by Type
  • One-dose Type
  • Two-dose Type
Segment by Application
  • Piglet
  • Adult Pig
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Boehringer Ingelheim, Zoetis, Merck, Pharmgate, Ceva, Huizhong Biological, Jiangsu Nannong Hi-Tech, SPAH, Jinyu Biotechnology
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market report?

Ans: The main players in the Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market are Boehringer Ingelheim, Zoetis, Merck, Pharmgate, Ceva, Huizhong Biological, Jiangsu Nannong Hi-Tech, SPAH, Jinyu Biotechnology

What are the Application segmentation covered in the Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market report?

Ans: The Applications covered in the Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market report are Piglet, Adult Pig

What are the Type segmentation covered in the Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market report?

Ans: The Types covered in the Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market report are One-dose Type, Two-dose Type

1 Study Coverage
1.1 Introduction to Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 One-dose Type
1.2.3 Two-dose Type
1.3 Market Segmentation by Application
1.3.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Piglet
1.3.3 Adult Pig
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Estimates and Forecasts 2020-2031
2.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Estimates and Forecasts 2020-2031
2.4 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 One-dose Type Market Size by Manufacturers
3.5.2 Two-dose Type Market Size by Manufacturers
3.6 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales and Revenue by Type (2020-2031)
6.4 North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales and Revenue by Type (2020-2031)
7.4 Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales and Revenue by Type (2020-2031)
9.4 Central and South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Corporation Information
11.1.2 Boehringer Ingelheim Business Overview
11.1.3 Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Models, Descriptions and Specifications
11.1.4 Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Product in 2024
11.1.6 Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Application in 2024
11.1.7 Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Area in 2024
11.1.8 Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine SWOT Analysis
11.1.9 Boehringer Ingelheim Recent Developments
11.2 Zoetis
11.2.1 Zoetis Corporation Information
11.2.2 Zoetis Business Overview
11.2.3 Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Models, Descriptions and Specifications
11.2.4 Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Product in 2024
11.2.6 Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Application in 2024
11.2.7 Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Area in 2024
11.2.8 Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine SWOT Analysis
11.2.9 Zoetis Recent Developments
11.3 Merck
11.3.1 Merck Corporation Information
11.3.2 Merck Business Overview
11.3.3 Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Models, Descriptions and Specifications
11.3.4 Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Product in 2024
11.3.6 Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Application in 2024
11.3.7 Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Area in 2024
11.3.8 Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine SWOT Analysis
11.3.9 Merck Recent Developments
11.4 Pharmgate
11.4.1 Pharmgate Corporation Information
11.4.2 Pharmgate Business Overview
11.4.3 Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Models, Descriptions and Specifications
11.4.4 Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Product in 2024
11.4.6 Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Application in 2024
11.4.7 Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Area in 2024
11.4.8 Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine SWOT Analysis
11.4.9 Pharmgate Recent Developments
11.5 Ceva
11.5.1 Ceva Corporation Information
11.5.2 Ceva Business Overview
11.5.3 Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Models, Descriptions and Specifications
11.5.4 Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Product in 2024
11.5.6 Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Application in 2024
11.5.7 Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Area in 2024
11.5.8 Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine SWOT Analysis
11.5.9 Ceva Recent Developments
11.6 Huizhong Biological
11.6.1 Huizhong Biological Corporation Information
11.6.2 Huizhong Biological Business Overview
11.6.3 Huizhong Biological Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Models, Descriptions and Specifications
11.6.4 Huizhong Biological Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Huizhong Biological Recent Developments
11.7 Jiangsu Nannong Hi-Tech
11.7.1 Jiangsu Nannong Hi-Tech Corporation Information
11.7.2 Jiangsu Nannong Hi-Tech Business Overview
11.7.3 Jiangsu Nannong Hi-Tech Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Models, Descriptions and Specifications
11.7.4 Jiangsu Nannong Hi-Tech Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Jiangsu Nannong Hi-Tech Recent Developments
11.8 SPAH
11.8.1 SPAH Corporation Information
11.8.2 SPAH Business Overview
11.8.3 SPAH Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Models, Descriptions and Specifications
11.8.4 SPAH Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 SPAH Recent Developments
11.9 Jinyu Biotechnology
11.9.1 Jinyu Biotechnology Corporation Information
11.9.2 Jinyu Biotechnology Business Overview
11.9.3 Jinyu Biotechnology Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Models, Descriptions and Specifications
11.9.4 Jinyu Biotechnology Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Jinyu Biotechnology Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Chain
12.2 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Boehringer Ingelheim
Zoetis Inc
Merck
Pharmgate
Ceva
SPAH
Jinyu Biotechnology
Huizhong Biological
Jiangsu Nannong Hi-Tech
List of Tables
 Table 1. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
 Table 7. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region (2020-2025) & (K Dose)
 Table 8. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region (2026-2031) & (K Dose)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Manufacturers (2020-2025) & (K Dose)
 Table 11. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Share by Manufacturers (2020-2025)
 Table 12. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine as of 2024)
 Table 16. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
 Table 18. Key Manufacturers Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Manufacturing Base and Headquarters
 Table 19. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Type (2020-2025) & (K Dose)
 Table 23. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Type (2026-2031) & (K Dose)
 Table 24. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine ASP by Type (2020-2031) & (US$/Dose)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Application (2020-2025) & (K Dose)
 Table 29. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Application (2026-2031) & (K Dose)
 Table 30. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine ASP by Application (2020-2031) & (US$/Dose)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Growth Accelerators and Market Barriers
 Table 37. North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Growth Accelerators and Market Barriers
 Table 40. Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Investment Opportunities and Key Challenges
 Table 47. Central and South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Boehringer Ingelheim Corporation Information
 Table 51. Boehringer Ingelheim Description and Major Businesses
 Table 52. Boehringer Ingelheim Product Models, Descriptions and Specifications
 Table 53. Boehringer Ingelheim Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 54. Boehringer Ingelheim Sales Value Proportion by Product in 2024
 Table 55. Boehringer Ingelheim Sales Value Proportion by Application in 2024
 Table 56. Boehringer Ingelheim Sales Value Proportion by Geographic Area in 2024
 Table 57. Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine SWOT Analysis
 Table 58. Boehringer Ingelheim Recent Developments
 Table 59. Zoetis Corporation Information
 Table 60. Zoetis Description and Major Businesses
 Table 61. Zoetis Product Models, Descriptions and Specifications
 Table 62. Zoetis Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 63. Zoetis Sales Value Proportion by Product in 2024
 Table 64. Zoetis Sales Value Proportion by Application in 2024
 Table 65. Zoetis Sales Value Proportion by Geographic Area in 2024
 Table 66. Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine SWOT Analysis
 Table 67. Zoetis Recent Developments
 Table 68. Merck Corporation Information
 Table 69. Merck Description and Major Businesses
 Table 70. Merck Product Models, Descriptions and Specifications
 Table 71. Merck Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 72. Merck Sales Value Proportion by Product in 2024
 Table 73. Merck Sales Value Proportion by Application in 2024
 Table 74. Merck Sales Value Proportion by Geographic Area in 2024
 Table 75. Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine SWOT Analysis
 Table 76. Merck Recent Developments
 Table 77. Pharmgate Corporation Information
 Table 78. Pharmgate Description and Major Businesses
 Table 79. Pharmgate Product Models, Descriptions and Specifications
 Table 80. Pharmgate Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 81. Pharmgate Sales Value Proportion by Product in 2024
 Table 82. Pharmgate Sales Value Proportion by Application in 2024
 Table 83. Pharmgate Sales Value Proportion by Geographic Area in 2024
 Table 84. Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine SWOT Analysis
 Table 85. Pharmgate Recent Developments
 Table 86. Ceva Corporation Information
 Table 87. Ceva Description and Major Businesses
 Table 88. Ceva Product Models, Descriptions and Specifications
 Table 89. Ceva Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 90. Ceva Sales Value Proportion by Product in 2024
 Table 91. Ceva Sales Value Proportion by Application in 2024
 Table 92. Ceva Sales Value Proportion by Geographic Area in 2024
 Table 93. Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine SWOT Analysis
 Table 94. Ceva Recent Developments
 Table 95. Huizhong Biological Corporation Information
 Table 96. Huizhong Biological Description and Major Businesses
 Table 97. Huizhong Biological Product Models, Descriptions and Specifications
 Table 98. Huizhong Biological Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 99. Huizhong Biological Recent Developments
 Table 100. Jiangsu Nannong Hi-Tech Corporation Information
 Table 101. Jiangsu Nannong Hi-Tech Description and Major Businesses
 Table 102. Jiangsu Nannong Hi-Tech Product Models, Descriptions and Specifications
 Table 103. Jiangsu Nannong Hi-Tech Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 104. Jiangsu Nannong Hi-Tech Recent Developments
 Table 105. SPAH Corporation Information
 Table 106. SPAH Description and Major Businesses
 Table 107. SPAH Product Models, Descriptions and Specifications
 Table 108. SPAH Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 109. SPAH Recent Developments
 Table 110. Jinyu Biotechnology Corporation Information
 Table 111. Jinyu Biotechnology Description and Major Businesses
 Table 112. Jinyu Biotechnology Product Models, Descriptions and Specifications
 Table 113. Jinyu Biotechnology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 114. Jinyu Biotechnology Recent Developments
 Table 115. Key Raw Materials Distribution
 Table 116. Raw Materials Key Suppliers
 Table 117. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 118. Milestones in Production Technology Evolution
 Table 119. Distributors List
 Table 120. Market Trends and Market Evolution
 Table 121. Market Drivers and Opportunities
 Table 122. Market Challenges, Risks, and Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources


List of Figures
 Figure 1. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Picture
 Figure 2. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. One-dose Type Product Picture
 Figure 4. Two-dose Type Product Picture
 Figure 5. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Piglet
 Figure 7. Adult Pig
 Figure 8. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Report Years Considered
 Figure 9. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 10. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 11. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 12. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2020-2031)
 Figure 13. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (2020-2031) & (K Dose)
 Figure 14. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (CAGR) by Region (2020-2031) (K Dose)
 Figure 15. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2020-2031)
 Figure 16. Top 5 and Top 10 Manufacturers Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Market Share in 2024
 Figure 17. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Ranking (2024)
 Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 19. One-dose Type Revenue Market Share by Manufacturer in 2024
 Figure 20. Two-dose Type Revenue Market Share by Manufacturer in 2024
 Figure 21. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2020-2031)
 Figure 22. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2020-2031)
 Figure 23. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2020-2031)
 Figure 24. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2020-2031)
 Figure 25. North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 26. North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. North America Top 5 Manufacturers Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) in 2024
 Figure 28. North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume (K Dose) by Type (2020- 2031)
 Figure 29. North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 30. North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 31. North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 32. US Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 33. Canada Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 34. Mexico Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 35. Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 36. Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 37. Europe Top 5 Manufacturers Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) in 2024
 Figure 38. Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume (K Dose) by Type (2020-2031)
 Figure 39. Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 40. Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 41. Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 42. Germany Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 43. France Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 44. U.K. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 45. Italy Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 46. Russia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 47. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 48. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific Top 8 Manufacturers Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) in 2024
 Figure 50. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume (K Dose) by Type (2020- 2031)
 Figure 51. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 52. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 53. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 54. Indonesia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 55. Japan Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 56. South Korea Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 57. China Taiwan Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 58. India Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 59. Central and South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 60. Central and South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 61. Central and South America Top 5 Manufacturers Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) in 2024
 Figure 62. Central and South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume (K Dose) by Type (2021-2031)
 Figure 63. Central and South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 64. Central and South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 65. Central and South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 66. Brazil Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 67. Argentina Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 68. Middle East, and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 69. Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 70. Middle East and Africa Top 5 Manufacturers Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) in 2024
 Figure 71. Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume (K Dose) by Type (2021-2031)
 Figure 72. South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 73. Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 74. Middle East and Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 75. GCC Countries Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 76. Turkey Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 77. Egypt Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 78. South Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 79. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Chain Mapping
 Figure 80. Regional Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Manufacturing Base Distribution (%)
 Figure 81. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Production Market Share by Region (2020-2031)
 Figure 82. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Production Process
 Figure 83. Regional Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Production Cost Structure
 Figure 84. Channels of Distribution (Direct Vs Distribution)
 Figure 85. Bottom-up and Top-down Approaches for This Report
 Figure 86. Data Triangulation
 Figure 87. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Mycoplasma Hyopneumoniae Vaccine Market Research Report 2024
Swine Mycoplasma Pneumonia Live Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Porcine Circovirus Diseases Vaccine Market Research Report 2024
Porcine Circovirus Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Swine Mycoplasma Hyopneumoniae Vaccine Market Research Report 2025
Inactivated Vaccine for Swine Mycoplasma Pneumonia Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Swine Mycoplasma Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Swine Circovirus Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Porcine Circovirus Type 2 PCV2 Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Mycoplasma Galliscepticum Vaccine Market Research Report 2024
Global Swine Parvovirus Disease Vaccine Market Research Report 2024
Global 23 Valent Pneumococcal Polysaccharide Vaccine Market Research Report 2024
Global Pneumococcal 13 valent Conjugate Vaccine Market Research Report 2024
Cervical Cancer Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccine for Porcine Reproductive and Respiratory Syndrome PRRS Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Equine Rhinopneumonitis Vaccine Market Research Report 2024
Swine Influenza Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Polyvalent Streptococcus Pneumococcal Vaccines Market Research Report 2025
Pneumococcal Vaccine Polyvalent Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions